SLC5A2 and type 2 diabetes mellitus: Prospective evaluation of dual therapy with GLP-1R agonists and SGLT2 inhibitors on cardiovascular outcomes is of great interest to assess if a synergistic effect exists with multimodal inhibition of pathological pathways in patients with and without type 2 diabetes.